JCRRF (JCR Pharmaceuticals Co) EBIT: $24.0 Mil (TTM As of Dec. 2025)


JCRRF JCR Pharmaceuticals Co Ltd JCRRF
65 GF Score
Price $3.15
GF Value $4.97
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is JCR Pharmaceuticals Co EBIT?

JCR Pharmaceuticals Co JCRRF 65 EBIT is $24.0 Mil as of Dec. 2025. GuruFocus rates JCRRF with a GF Score™ of 65/100 and a GF Value™ of $4.97 (Possible Value Trap). The stock has 8 warning signs investors should review.

JCR Pharmaceuticals Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $2.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $24.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JCR Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2025 was -2.89%. JCR Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. JCR Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.06%.

JCR Pharmaceuticals Co  (OTCPK:JCRRF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JCR Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-50.08 * ( 1 - 61.47% )/( (671.656 + 662.149)/ 2 )
=-19.295824/666.9025
=-2.89 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=737.541 - 9.583 - ( 105.645 - max(0, 321.298 - 377.6+105.645))
=671.656

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=726.716 - 12.013 - ( 100.33 - max(0, 322.772 - 375.326+100.33))
=662.149

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

JCR Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9.8/( ( (251.118 + max(143.099, 0)) + (254.498 + max(194.42, 0)) )/ 2 )
=9.8/( ( 394.217 + 448.918 )/ 2 )
=9.8/421.5675
=2.32 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(92.281 + 158.336 + 21.338) - (9.583 + 0 + 119.273)
=143.099

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(95.11 + 159.722 + 20.164) - (12.013 + 0 + 68.563)
=194.42

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

JCR Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=24.006/591.506
=4.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JCR Pharmaceuticals Co EBIT Related Terms

JCR Pharmaceuticals Co EBIT Historical Data

* Premium members only.

The historical data trend for JCR Pharmaceuticals Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JCR Pharmaceuticals Co EBIT Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 164.02 40.82 48.93 -41.99 22.83

JCR Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.56 -4.65 22.79 2.45 3.42

JCRRF vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JCR Pharmaceuticals Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's EV-to-EBIT falls into.


JCRRF
65GF Score
JCR Pharmaceuticals Co Ltd JCRRF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JCR Pharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $24.0 Mil mean?
JCR Pharmaceuticals Co (JCRRF) has a EBIT of $24.0 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on JCR Pharmaceuticals Co.
Is JCR Pharmaceuticals Co's EBIT too high?
JCR Pharmaceuticals Co's current EBIT is $24.0 Mil. Overall, JCR Pharmaceuticals Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's EBIT compare to LLY and JNJ?
JCR Pharmaceuticals Co's EBIT of $24.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on JCR Pharmaceuticals Co. JCR Pharmaceuticals Co's current EBIT is $24.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (JCRRF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.97, compared to a current price of $3.15 — trading 36.7% below its estimated fair value. The current EBIT is $24.0 Mil. JCR Pharmaceuticals Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For JCR Pharmaceuticals Co (JCRRF), the current EBIT is $24.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JCR Pharmaceuticals Co (JCRRF) Overvalued in 2026?

Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued. The current stock price of $3.15 is trading 36.7% below its estimated GF Value™ of $4.97. GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for JCRRF:

  • EBIT: $24.0 Mil
  • GF Value™: $4.97 vs. price of $3.15 (36.7% below fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the JCRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JCR Pharmaceuticals Co Business Description

Other Exchanges 4552:Japan
Address 3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
65GF Score

Get the complete analysis for JCRRF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.15
Price
$4.97
GF Value